‘Seeing the evolution’: As branded patent cliff looms, biosimilar experts size up US hurdles, opportunities ahead

The tables have turned for the U.S. biosimilars market.  | With more than a decade passed since the first FDA biosim approval, strong launches of biologic copies to AbbVie’s Humira, J&J’s Stelara and Regeneron/Bayer’s Eylea are shifting a narrative once focused on lagging uptake of the category in The States.